Login to Your Account



Amorchem spinout Mperia advancing CD36 drug-ligand in dry AMD

By Jennifer Boggs
Managing Editor

Monday, April 17, 2017

When going after macrophages, "in my view, you play directly with the immune system," said Maxime Ranger, president and CEO of Mperia Therapeutics Inc., which is advancing macrophage-targeting immunotherapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription